BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 13, 2010
View Archived Issues
Nonselective inhibitor pandacostat discovered by chemical phylogenetic analysis of HDACs
Read More
Enanta Pharmaceuticals describes new antiviral agents
Read More
Merck Frosst claims new prostanoid DP2 receptor antagonists
Read More
Roche discovers novel inhibitors of Mdm2/p53 interaction
Read More
AEgera Therapeutics discloses new apoptosis inducers
Read More
Jerini identifies novel bradykinin B2 receptor ligands
Read More
Novartis optimizes lysophospholipid receptor S1P1 agonists
Read More
Raloxifene decreases epistaxis in hereditary hemorrhagic telangiectasia / News in Context
Read More
Johnson & Johnson reports new HIF prolyl hydroxylase inhibitors
Read More
Gaucher's disease patients achieve key therapeutic goals with velaglucerase alfa
Read More
Vantia discloses dysmenorrhea candidate VA-111913 at ACS meeting
Read More
Ziopharm Oncology begins phase I/II indibulin trial in breast cancer
Read More
Cedars-Sinai Medical Center launches two-drug trial in brain tumors
Read More
Transdel Pharmaceuticals raises funds for Ketotransdel trial
Read More
HRA licences additional rights for Esmya to PregLem for benign gynecological disorders
Read More
Ark Therapeutics' EG-01257 reduces tumor growth in preclinical studies
Read More
FDA issues complete response letter for ChemGenex's Omapro in CML
Read More
MaxCyte and Medinet expand license agreement for cell loading technology
Read More
Pervasis begins enrollment in phase I/II trial of PVS-10200 for restenosis prevention
Read More
Javelin intends to terminate merger agreement with Myriad following offer from Hospira
Read More
New phase II CERE-110 trial in Alzheimer's disease set to begin
Read More
Horizon Therapeutics and Nitec merge to form Horizon Pharma
Read More
MediGene licenses oHSV development program to Catherex
Read More
Gilead initiates phase III clinical Quad program in HIV
Read More
Inhibitex's phase II FV-100 trial in shingles continues as planned
Read More